Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 oct. 2025 07h00 HE | Source: Biomed Valley Discoveries, Inc.

Biomed Valley Discoveries Announces Publication of Results from Phase 1b Study of Pembrolizumab in Combination with Clostridium novyi-NT (CNV-NT/BVD-550) in Patients with Advanced Solid Tumors in Clinical Cancer Research

Biomed Valley Discoveries announces publication of Phase 1b study findings of pembrolizumab in combination with Clostridium novyi-NT (CNV-NT/BVD-550).
28 avr. 2025 07h00 HE | Source: Biomed Valley Discoveries, Inc.

Biomed Valley Discoveries Announces First Patient Dosed in Phase 1/2 Combination Study of Ulixertinib with Ruxolitinib (Jakafi®) in Patients with Myelofibrosis

Biomed Valley Discoveries announces first patient dosed in Phase 1/2 Combination Study of ulixertinib with ruxolitinib in patients with myelofibrosis.
13 août 2024 08h00 HE | Source: Biomed Valley Discoveries, Inc.

Biomed Valley Discoveries Announces First Patient Dosed in Phase 2 Study of Its First-in-Class ERK 1/2 Inhibitor Ulixertinib in People with Histiocytosis

Biomed Valley Discoveries today announced that the first patient has been dosed in a Phase 2 study of ulixertinib for the treatment of histiocytosis.